Are heart doses associated with survival in patients with non-small cell lung cancer who received post-operative thoracic radiotherapy?: A national population-based study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
17
9
2019
Statut:
ppublish
Résumé
The aim of this retrospective national cohort study is to assess the association between various radiation heart dosimetric parameters (RHDPs), acute myocardial infarct (AMI) and overall survival (OS) outcomes in non-small cell lung cancer (NSCLC) patients treated with post-operative thoracic radiotherapy (PORT) using contemporary radiation techniques.We identified patients with stage I to III NSCLC treated with PORT at the 2 national cancer institutions from 2007 to 2014. We linked their electronic medical records to the national AMI and death registries. Univariable Cox regression was performed to assess the association between various RHDPs, AMI, and OS.We included 43 eligible patients with median follow-up of 36.6 months. Median age was 64 years. Majority of the patients had pathological stage III disease (72%). Median prescription dose was 60Gy. Median mean heart dose (MHD) was 9.4Gy. There were no AMI events. The 5-year OS was 34%. Univariable Cox regression showed that age was significantly associated with OS (hazard ratio, 1.06; 95% confidence interval, 1.01 to 1.10; P = .008). Radiation heart doses, including MHD, volume of heart receiving at least 5, 25, 30, 40, 50Gy and dose to 30% of heart volume, were not significantly associated with OS.There is insufficient evidence to conclude that RHDPs are associated with OS for patients with NSCLC treated with PORT in this study. Studies with larger sample size and longer term follow-up are needed to assess AMI outcome.
Identifiants
pubmed: 31464961
doi: 10.1097/MD.0000000000017020
pii: 00005792-201908300-00073
pmc: PMC6736475
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e17020Références
J Thorac Oncol. 2017 Feb;12(2):293-301
pubmed: 27743888
Radiother Oncol. 2016 Jun;119(3):495-500
pubmed: 27189523
J Thorac Oncol. 2015 Jan;10(1):148-55
pubmed: 25325781
J Clin Oncol. 2006 Jul 1;24(19):2998-3006
pubmed: 16769986
J Clin Oncol. 2003 Sep 15;21(18):3431-9
pubmed: 12885835
Radiother Oncol. 2014 Jan;110(1):3-8
pubmed: 24100149
Lancet. 1998 Jul 25;352(9124):257-63
pubmed: 9690404
Onco Targets Ther. 2016 Feb 24;9:921-8
pubmed: 26966380
J Clin Oncol. 2017 Jan;35(1):56-62
pubmed: 28034064
Radiother Oncol. 2017 Nov;125(2):293-300
pubmed: 29050957
Ann Intern Med. 2007 Nov 6;147(9):633-8
pubmed: 17975186
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
J Clin Oncol. 2015 Mar 10;33(8):870-6
pubmed: 25667283
Cancer. 1999 Jul 15;86(2):265-73
pubmed: 10421262
Lancet. 2005 Dec 17;366(9503):2087-106
pubmed: 16360786
Ann Oncol. 2010 Sep;21(9):1825-1833
pubmed: 20211871
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):695-701
pubmed: 18439766
J Thorac Oncol. 2016 Nov;11(11):1940-1953
pubmed: 27393474
Cancer. 2007 Aug 15;110(4):911-7
pubmed: 17620279
J Clin Oncol. 2017 May 1;35(13):1387-1394
pubmed: 28113017
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Cochrane Database Syst Rev. 2016 Oct 11;10:CD002142
pubmed: 27727451
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
J Clin Oncol. 2017 May 1;35(13):1395-1402
pubmed: 28301264
Pathol Res Pract. 1994 Feb;190(2):115-23
pubmed: 8058567
Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1106-13
pubmed: 19560881